首页> 外文OA文献 >A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

【2h】

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

机译：精神分裂症患者奥兰扎宁长效注射效果和安全性的6年开放式研究：基于欧洲标签推荐的后HOC分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ernie Anand; Lovisa Berggren; Claudia Deix; Ágoston Tóth; David McDonnell;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation [J] . Ernie Anand, Lovisa Berggren, Claudia Deix, Neuropsychiatric Disease and Treatment . 2015,第1期

机译：奥氮平长效注射剂在精神分裂症患者中的有效性和安全性的6年开放标签研究：基于欧洲标签推荐的事后分析
2. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study [J] . McDonnell David P., Landry John, Detke Holland C. International clinical psychopharmacology . 2014,第6期

机译：奥氮平长效注射剂对精神分裂症或精神分裂症患者的长期安全性和有效性：一项为期6年的多国单臂开放标签研究
3. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study [J] . McDonnell David P., Landry John, Detke Holland C. International clinical psychopharmacology . 2014,第6期

机译：精神分裂症患者奥兰齐滨长效注射液的长期安全性和疗效：6年，跨国，单臂，开放标签研究
4. An open-label, multicenter, randomized,comparative, safety, efficacy, cycle control,and quality of life study of CTR 25, Alesse ,and Ortho Tri-Cyclen [C] . Victoria Davis, Brian Hauck, Sheila Dunn, World Congress on Fertility and Sterility . 2004

机译：开放标签，多中心，随机，比较，安全，疗效，循环控制和CTR 25，Alesse和Ortho Tri-Cyclen的生命研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation [O] . Ernie Anand, Lovisa Berggren, Claudia Deix, 2015

机译：奥氮平长效注射剂在精神分裂症患者中的有效性和安全性的6年开放标签研究：基于欧洲标签推荐的事后分析
7. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study [O] . 2015

机译：接受奥氮平长效注射治疗的精神分裂症患者的基线特征和住院治疗：一项非干预性前瞻性观察性安全性研究的中期分析

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

著录项

引文网络

相似文献

相关主题

期刊订阅